AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham speaks with Proactive after receiving the results of dose simulation studies that support the potential efficacy of its i-body drug candidate AD-214 in fibrotic disease at its planned intravenous dose regime. The simulations also highlight the possibility that AD-214 could be delivered subcutaneously at lower doses. He says the results of the studies — supporting both the potential efficacy of target intravenous doses of AD-214 and that subcutaneous administration could also be effective — reduce Phase II risk and significantly enhance AdAlta’s partnering potential.
AdAlta says new AD-214 dosing models enhance partnering potential
